Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Sungjin Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Purpose
Major pathologic response (MPR), defined as ≤ 10% of residual viable tumor (VT), is a prognostic factor in non–small cell lung cancer (NSCLC) after neoadjuvant therapy. This study evaluated interobserver reproducibility in assessing MPR, compared area-weighted and unweighted VT (%) calculation, and determined optimal VT (%) cutoffs across histologic subtypes for survival prediction.Materials and Methods This retrospective study included 108 patients with NSCLC who underwent surgical resection after neoadjuvant chemotherapy or chemoradiation at Seoul National University Bundang Hospital between 2009-2018. Three observers with varying expertise independently assessed tumor bed and VT (%) based on digital whole-slide images.
Results
Reproducibility in tumor bed delineation was reduced in squamous cell carcinoma (SqCC) with smaller tumor bed, although overall concordance was high (Dice coefficient, 0.96; intersection-over-union score, 0.92). Excellent agreement was achieved for VT (%) (intraclass correlation coefficient=0.959) and MPR using 10% cutoff (Fleiss’ kappa=0.911). Shifting between area-weighted and unweighted VT (%) showed only one case differing in MPR status out of 81 cases. The optimal cutoff was 10% for both adenocarcinoma (ADC) and SqCC. MPR+ was observed in 18 patients (17%), with SqCC showing higher MPR+ rates (p=0.044), lower VT (%) (p < 0.001), and better event-free survival (p=0.015) than ADC. MPR+ significantly improved overall survival (p=0.023), event-free survival (p=0.001), and lung cancer-specific survival (p=0.012).
Conclusion
While MPR assessment demonstrated robust reproducibility with minimal impact from the tumor bed, attention is warranted when evaluating smaller tumor beds in SqCC. A 10% cutoff reliably predicted survival across histologic subtypes with higher interobserver reproducibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, S., Lee, J., & Chung, J. H. (2025). Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.670
Vancouver
Kim S, Lee J, Chung JH. Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.670
BibTeX
@article{Kim2025,
author = {Kim, Sungjin and Lee, Jeonghyo and Chung, Jin-Haeng},
title = {Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.670}
}
EUVIMED